Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.

ABSTRACT:

Purpose

The numerous first-line treatment regimens for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) necessitate a comprehensive evaluation to inform clinical decision-making. We conducted a Bayesian network meta-analysis (NMA) to compare the efficacy and safety of different interventions.

Methods

We systematically searched for relevant randomized controlled trials (RCTs) in Pubmed, Embase, Cochrane Library and online abstracts from inception to June 1, 2023. NMA was performed to calculate and analyze progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events of grade 3 or higher (≥ 3 AEs).

Results

Out of the 10,313 manuscripts retrieved, we included 28 RCTs involving 11,680 patient

SUBMITTER: Wang J 

PROVIDER: S-EPMC10799814 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature